

REFERENCES

- Andriole V.T. Pharmacokinetics of cephalosporins in patients with normal or reduced renal function. *J. Infect. Dis.* 1978; 137(suppl): s88-s97.
- Bach V.T., Roy I, and Thadepalli H. Susceptibility of anerobic bacteria to cefoxitin and related compounds. *Antimicrob. Agents Chemother.* 1977; 11: 912-3.
- Balant L, Dayer P, Auckenthaler R. Clinical pharmacokinetics of the third generation cephalosporins. *Clin. Pharmacokinet.* 1985; 10:101-43.
- Barrueco M., Garcia M.J., Otero M.J., Dominquez-Gil A. and Martinez L de Letona J. Disposition of cefoxitin in patients with pleural effusion. *Clin. Ther.* 1981; 3: 425-35.
- Bawdon R.E., Henisell D.L. and Guss S.P. Comparison of cefoperazone and cefoxitin concentrations in serum and pelvic tissue of abdominal hysterectomy patients. *Antimicrob. Agents Chemother.* 1982; 22: 999-1003.
- Blanco J.D., Jorgensen J.H., Castaneda Y.S. and Crawford S.A. Ceftazidime levels in human breast milk. *Antimicrob. Agents Chemother.* 1983; 23:479-80.
- Bressolle F., Coussaye J., Coussaye E., Ayoub R., Fabre D., Gomeni R., Saissi G., Eledjam J. and Galtier M. Endotracheal and aerosol administration of ceftazidime in patients with nosocomial pneumonia: pharmacokinetics and absolute bioavailability. *Antimicrob. Agents Chemother.* 1992; 36: 1404-11.
- Brogden R.N., Heel R.C., Speight T.M. and Avery G.S. Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use. *Drugs* 1979; 17: 1-37.

- Brumfitt W., Kosmidis J., Hamilton-Miller J.M.T. and Gilchrist J.N.G. Cefoxitin and cephalothin: antimicrobial activity, human pharmacokinetics and toxicology. *Antimicrob. Agents Chemother.* 1974; 6: 290-4.
- Chien L., Hinthorn D.O., Hodges G.R., Harms J.L., Couchonnal G. and Dworzack D.L. Penetration of cefoxitin into the human cerebrospinal fluid: comparison with cefamandole, ampicillin and penicillin. *Rev. Infect. Dis.* 1979; 1: 127-31.
- Chow A.W. and Bednorz D. Comparative *in vitro* activity of newer cephalosporins against anaerobic bacteria. *Antimicrob. Agents Chemother.* 1978; 14: 668-71.
- Deeter R.G., Weinstein M.P., Swanson K.A., Gross J.S. and Bailey L. Crossover assessment of serum bactericidal activity and pharmacokinetics of five broad-spectrum cephalosporins in the elderly. *Antimicrob. Agents Chemother.* 1990; 34: 1007-1013.
- Dominquez J., Palma F., Vega M.E., Magana J.L., Ortiz G. Teresa-Hoiyo M. and Dominquez L. Brief report: prospective, controlled, randomized nonblind comparison of intravenous/oral ciprofloxacin with intravenous ceftazidime in the treatment of skin and soft tissue infections. *Am. J. Med.* 1989; 87: 136S-137S.
- Donowitz G.R., and Mandell G.L. Beta-lactam antibiotics. *N. Engl. J. Med.* 1988; 318: 419-426 and 490-450.
- Dubois M., Delapierre D., Chanteux L., Demonty J., Lambotte R., Kramp R. and Dresse A. A study of the transplacental transfer and the mammary excretion of cefoxitin in human. *J. Clin. Pharmacol.* 1981; 21: 477-83.
- Fong I.W., Tomkins K.B. Penetration of ceftazidime into the cerebrospinal fluid of patients with and without evidence of meningeal inflammation. *Antimicrob. Agents Chemother.* 1984; 26:115-6.

- Garcia M.J., Garcia A., Nieto M.J., Domínguez-Gil A. and Alonso G. Disposition of cefoxitin in the elderly. *Int. J. Clin. Pharmacol. Ther. Toxicol.* 1980; 18: 503-9.
- Geddes A.M., Schnurr L.P., Ball A.P., McGhie D., Brookes G.R., Wise R. and Andrews J. Cefoxitin : a hospital survey. *Br. Med. J.* 1977; 1: 1126-8.
- Giamarellou H., Gazis J., Petrikos G., Antsaklis A., Aravantinos D. and Daikos G.K. A study of cefoxitin, moxalactam, and ceftazidime kinetics in pregnancy. *Am. J. Obstet. Gynecol.* 1983; 147:914-9. 7
- Gillett A.P. and Wise R. Penetration of four cephalosporins into tissue fluid in man. *Lancet* 1978; 1: 962-4.
- Gonik B., Cotton D., Feldman S., Cleary T.G. and Pickering L.A. Comparative pharmacokinetics of cefoxitin in postpartum normotensive and pregnancy-induced hypertensive patients. *Am. J. Obstet. Gynecol.* 1984; 14: 1088-91.
- Greaves W.L., Kraus S.J., McCormack W.M., Biddle J.W., Zaidi A., Fiumara N.J. and Guinan M.E. Cefoxitin vs penicillin in the treatment of uncomplicated gonorrhoea. *Sex. Transm. Dis.* 1983; 10: 53-55.
- Hansbrough J.F. and Clark J.E. Concentration of cefoxitin in gallbladder bile of cholecystectomy patients. *Antimicrob. Agents Chemother.* 1982; 4: 709-10.
- Harding S.M., Monro A.J., Thornton J.E., Ayrton J. and Hogg M.I.J. The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers. *J. Antimicrob. Chemother.* 1981; 8(suppl.B):263-272.
- Hedman A., Adan-Abdi Y., Alvan G., Strandvik B. and Arvidsson A. Influence of glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis. *Clin. Pharmacokinet.* 1988; 15: 57-65.
- Heim-Duthoy K.L., Bubrick M.P., Cocchetto D.M. and Matzke G.R. Disposition of ceftazidime in surgical patients with intra-abdominal infection. *Antimicrob. Agents Chemother.* 1988; 32: 1845-1847.

- Humbert G., Fillastre J.P., Leroy A., Godin M. and Winzum C.V. Pharmacokinetics of cefoxitin in normal subjects and in patients with renal insufficiency. *Rev. Infect. Dis.* 1979; 1(2): 118-126.
- Kampf D., Schurig R., Korsukewitz I. and Bruckner O. Cefoxitin pharmacokinetics: relation to three difference renal clearance studies in patients with various degree of renal insufficiency. *Antimicrob. Agents Chemother.* 1981; 20: 741-6.
- Kass E.H. and Evans D.A. (eds). Future prospects and past problems in antimicrobial therapy : the role of cefoxitin. *Rev. Infect. Dis.* 1979; 1: 1-4.
- Kemmerich B., Warns H., Lode H., Borner K., Koeppe P, and Knothe H. Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. *Antimicrob. Agents Chemother.* 1983; 24:333-8.
- Kosmidis J., Hamilton-Miller J.M.T., Gilchrist J.N.G., Kerry D.W. and Brumfitt W. Cefoxitin, a new semi-synthetic cephamycin: an *in-vitro* and *in-vivo* comparison with cephalothin. *Br. Med. J.* 1973; 4: 653-655.
- Lam Y.W., Duroux M.H., Gambertoglio J.G., Barriere S.L. and Guglielmo B.J. Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers. *Antimicrob. Agents Chemother.* 1988; 32: 298-302.
- LeBel M., Barbeau G., Vallee F. and Bergeron M.G. Pharmacokinetics of ceftazidime in elderly volunteers. *Antimicrob. Agents Chemother.* 1985; 28:713-5.
- Leroy A., Leguy F., Borsa F., Spencer G.R., Fillastre J.P. and Humbert G. Pharmacokinetics of ceftazidime in normal and uremic subjects. *Antimicrob. Agents Chemother.* 1984; 25:638-42.
- Loebis L.H. Tissue levels in patients after intravenous administration of ceftazidime. *J. Antimicrob. Chemother.* 1985; 16:757-61.

- Luthy R., Blaser J., Bonetti A., Simmen H., Wise R. and Siegenthaler W. Comparative multiple-dose pharmacokinetics of cefoxitaxime, moxalactam, and ceftazidime. *Antimicrob. Agents Chemother.* 1981; 20(5): 567-575.
- Mays B., Short L., Hershman M.J. and Cheadle W.G. Relevance of protein binding to cephalosporin antimicrobial activity *in vivo*. *Chemotherapy* 1990; 36: 254-258.
- Neu H.C. and Labthavikul P. Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* 1982; 21: 11-8.
- Neu H.C. Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. *J. Infect. Dis.* 1978; 137: S80-S87.
- Nightingale C.H., Olson N. and Quintiliani R. Penetration of cefoxitin into the right atrial appendage and pericardial fluid of patients undergoing open heart operations. *Curr. Ther. Res.* 1981; 29: 444-51.
- O'Callaghan C.H., Acred P., Harper P.B., Ryan D.M., Kirby S.M. and Harding S.M. GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity. *Antimicrob. Agents Chemother.* 1980; 17:876-83.
- Paradis D., Vallee F., Allard S., Bisson C., Daviau N., Drapeau C., Auger F. and Lebel M. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. *Antimicrob. Agents Chemother.* 1992; 36(10): 2085-2092.
- Paulfeuerborn W., Muller H., Muller J., Borner K., Koeppel P. and Lode H. Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime. *Antimicrob. Agents Chemother.* 1993; 37: 1835-1841.

- Reeves D.S., Bullock D.W., Bywater M.J., Holt H.A., White L.O. and Thornhill D.P. The effect of probencid on the pharmacokinetics and distribution of cefoxitin in healthy volunteers. *Br. J. Clin. Pharmacol.* 1981; 11:353-359.
- Reinhardt J.F., Bacon A.E., Winslow D.L. and Holloway W.J. Brief report: ciprofloxacin versus ceftazidime in serious infections. *Am. J. Med.* 1989; 87: 181S-182S.
- Richards D.M. and Brogden R.N. Ceftazidime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. *Drugs* 1985; 29: 105-61.
- Schrogie J.J., Davies R.O., Yeh K.C., Rogers D., Holmes G.I., Skeggs H. and Martin C.M. Bioavailability and pharmacokinetics of cefoxitin sodium. *J. Antimicrob. Chemother.* 1978; 4 (Suppl.B): 69-78.
- Schrogie J.J., Rogers J.D., Yeh K.C., Rogers D., Holmes G.I., Skeggs H. and Martin C.M. Pharmacokinetics and comparative pharmacology of cefoxitin and cephalosporins. *Rev. Infect. Dis.* 1979; 1(2): 90-98.
- Shiramatsu K., Hirata K., Yamada T., Kimura H. and Hayasaka H. Ceftazidime concentration in gallbladder tissue and excretion in bile. *Antimicrob. Agents Chemother.* 1988; 32:1588-9.
- Sommers D.K., Walters L., Wyk M.V., Harding S.M., Paton A.M. and Ayrton J. Pharmacokinetics of ceftazidime in male and female volunteers. *Antimicrob. Agents Chemother.* 1983; 23:892-6.
- Sonneville P.F., Albert K.S., Skeggs H., Gentner H., Kwan K.C. and Martin C.M. Effect of lidocaine on the absorption, disposition and tolerance of intramuscular administered cefoxitin. *Eur. J. Clin. Pharmacol.* 1977; 12: 273.
- Sutter V.L. and Finegold S.M. Susceptibility of anaerobic bacteria to carbennicillin, cefoxitin, and related drugs. *J. Infect. Dis.* 1975; 131: 417-22.

- Tjandramaga T.B., Hecken A.V., Mullie A., Verbesselt R., De Schepper P.J. and Verbist L. Comparative pharmacokinetic of ceftazidime and moxalactam. *Antimicrob. Agents Chemother.* 1982; 22(2): 237-241.
- Trenholme G.M., Schmitt B.A., Spear J., Gvazdinskas L.C. and Levin S. Randomized study of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections. *Am. J. Med.* 1989; 87: 116S-118S.
- Turner A., Pedler S.J., Carswell F., Spencer G.R. and Speller D.C.E. Serum and sputum concentrations of ceftazidime in patients with cystic fibrosis. *J. Antimicrob. Chemother.* 1984; 14:521-7.
- Villavicencio J., Asensio de Fernandez M.E. and Ramirez C.A. Intravenous ciprofloxacin or ceftazidime in selected infections: prospective, randomized controlled study. *Am. J. Med.* 1989; 87: 191S-194S.
- Vlasses P.H., Holbrook A.M., Schrogie J.J., Rogers J.D., Ferguson R.K. and Abrams W.B. Effect of orally administered probenecid on the pharmacokinetics of cefoxitin. *Antimicrob. Agents Chemother.* 1980; 17: 847-55.
- Wallick H. and Hendlin D. Cefoxitin, a semisynthetic cephamycin antibiotic: susceptibility studies. *Antimicrob. Agents Chemother.* 1974; 5: 25-32.
- Winzum C.V. Clinical safety and tolerance of cefoxitin sodium: an overview. *J. Antimicrob. Chemother.* 1978; 4(Suppl.B): 91-96.
- Yost R.L. and Derendorf H. Rapid chromatographic determination of cefotaxime and its metabolite in biological fluids. *J. Chrom. Biomed. Appli.* 1986; 341: 131-38.